
Lunai Bioworks fell 98.6% from $11.52 to $0.16, behind the S&P 500's +5.7%. Its worst day was Oct 23 (−37.3%), and its low came Oct 29 at $0.16.
Nov 20, 2025 – Oct 29, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.64 was reported on $0.00 revenue.
−9.2% · S&P 500 +0.2%
Lunai Bioworks shares rose 162.8%, while the S&P 500 rose 0.3%.
+162.8%, the year's best day, on 69M shares, the year's heaviest volume · S&P 500 +0.3%
Story events cover the past 12 months · Times ET
Advancing AI-enabled chemical threat detection and dual-use biodefense technologies through initial commercial deploymentSACRAMENTO, Calif., April 7, 2026 /PRNewswire/ -- Lunai Bioworks, Inc.
+39.8% · S&P 500 0.0%
EPS of $-0.80 was reported on $20,942.00 revenue.
+0.5% · S&P 500 −0.1%
Lunai Bioworks shares rose 40.6%, while the S&P 500 fell 1.5%.
+40.6% · S&P 500 −1.5%
EPS of $-0.50 was reported on $31,050.00 revenue.
−13.4% · S&P 500 −1.1%
Lunai Bioworks shares fell 37.3%, while the S&P 500 fell 0.5%.
−37.3%, the year's worst day · S&P 500 −0.5%
Where it ended: a close of $0.16 on Oct 29, 2026. Up next: Q1 2027 earnings on Dec 1, 2026.
Nothing in the past 12 months.
All LNAI analyst actionsNothing in the past 12 months.
All LNAI dividend history